Jonathan McNeill - Mar 13, 2023 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Signature
/s/ Richard Scalzo, Attorney-in-Fact
Stock symbol
DYN
Transactions as of
Mar 13, 2023
Transactions value $
-$29,116
Form type
4
Date filed
3/15/2023, 05:50 PM
Previous filing
Jan 23, 2023
Next filing
Jun 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DYN Common Stock Sale -$13K -1K -1.48% $13.00 66.6K Mar 13, 2023 Direct F1, F2, F3
transaction DYN Common Stock Sale -$16.1K -1.21K -1.82% $13.33 65.4K Mar 14, 2023 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.00 to $13.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
F3 Includes 63,408 unvested RSUs.
F4 Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

Remarks:

Senior Vice President of Business Development